脑部放疗，上午比下午敏感许多！( `+ F7 d E- ^0 ~$ c
6 |( k& l& u" V" V
0 ], B# X* _+ i$ a' @2 x2 J
Cancer 2011 Jan 15;117(2):414-20. doi: 10.1002/cncr.25423. Epub 2010 Sep 9.' s! t1 a% G3 N! q# N& y/ [3 k8 {
Gamma knife radiosurgery for brain metastasis of nonsmall cell lung cancer: is there a difference in outcome between morning and afternoon treatment?# p; U# t$ b9 \: Q/ {7 ]7 d3 M$ y* A
Rahn DA 3rd, Ray DK, Schlesinger DJ, Steiner L, Sheehan JP, O'Quigley JM, Rich T.
/ o1 K. g' a) e# j* l! VSourceDepartment of Radiation Oncology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA.3 }3 n' ^3 n- I' E1 R4 T( k
0 D, |8 C3 O/ O6 i( ^5 \' eAbstract
5 |0 K; F2 r3 c' ABACKGROUND: Circadian cell-cycle progression causes fluctuating radiosensitivity in many tissues, which could affect clinical outcomes. The purpose of this study was to determine whether outcomes of single-session gamma knife radiosurgery (GKRS) for metastatic nonsmall cell lung cancer (NSCLC) differ based on treatment time.
) w L. {1 H8 W6 @- o9 ~1 ]* `# `9 ?( ~5 ?) k
METHODS: Fifty-eight patients received GKRS between 10:00 am and 12:30 pm and 39 patients received GKRS between 12:30 pm and 3:00 pm. The mean peripheral dose was 18.6 Gy. The mean tumor size was 7.3 cm³. Magnetic resonance imaging was used to score local control at 3 months. Cause of death (COD) was categorized as central nervous system (CNS)-related or systemic.: `; ?& r. ]4 z& |; Q9 B9 \* x
/ \$ Z" A' F$ h2 n% L" K/ E
RESULTS: Demographic and disease characteristics of the 2 groups were similar. Local control at 3 months was achieved in 97% (35/36) of patients who underwent GKRS early in the day versus 67% (8/12) of patients who underwent GKRS later in the day (chi-square, P = .014). Early GKRS was associated with better survival (median 9.5 months) than late GKRS (median 5 months) (Kaplan-Meier log-rank test, P = .025). Factors contributing to better survival in a Cox regression model included early treatment time (P = .004) and recursive partition analysis class (P < .001). Cause of death in the early treatment group was CNS-related in 6% (3/47) of patients versus 24% (8/34) of patients in the late treatment group (chi-square test, P = .026).1 I! X5 l- t4 h( n8 L. p3 ?" g- w
8 ]4 N1 b* e7 x. [' n5 f/ y" s
CONCLUSIONS: GKRS for metastatic NSCLC had better local control, better survival, and a lower rate of CNS-related cause of death when given earlier in the day versus later in the day. These retrospective data should encourage future study in brain radiosurgery and non-CNS stereotactic body radiotherapy series.; g1 y$ u7 ^: z0 s# q1 u
4 S n: K3 I9 |' f/ H
|
母亲晚期肺癌跨越11年了！我们的5点
讲述者：小白兔整理者：pear
2014年母亲确诊晚期肺腺癌，一路摸索抗癌前行，幸得病友
根治性放疗结束后，免疫维持两年能不
家父2022年12月份确诊右肺上叶肺鳞癌3A期，纵膈淋巴结转移，一直在复肿治疗，先新辅助
无靶点 her2扩增 二线白紫耐药后怎么
家父今年62岁，22年11月份颈部淋巴结穿刺，确诊肺低分化腺癌，分期是TxN3M1，基因检测
卡度联合安罗，谁让肿瘤缩小了
肺低分化腺，伴肉瘤样。卡度尼利单抗联合安罗替尼。两个疗程复查显示肿瘤缩小，胸膜增
褚倩教授、范云教授：肺癌MET变异检
整理者：雨过天晴审核人：鹰版为帮助MET基因异常等少见靶点NSCLC患者解决在治疗过程中
显身卡
# U/ O9 w4 t" ^3 n( |6 x
